DepoMed to buy U.S. rights to Nucynta from J&J unit
January 15, 2015 at 16:48 PM EST
DepoMed agrees to buy the U.S. license rights to the painkiller Nucynta from Janssen Pharmaceuticals, a unit of Johnson & Johnson, for $1.05 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.